Abstract

Schistosomiasis remains a health burden in many parts of the world. The complex life cycle of Schistosoma parasites and the economic and societal conditions present in endemic areas make the prospect of eradication unlikely in the foreseeable future. Continued and vigorous research efforts must therefore be directed at this disease, particularly since only a single World Health Organization (WHO)-approved drug is available for treatment. The National Institutes of Health (NIH)–National Institute of Allergy and Infectious Diseases (NIAID) Schistosomiasis Resource Center (SRC) at the Biomedical Research Institute provides investigators with the critical raw materials needed to carry out this important research. The SRC makes available, free of charge (including international shipping costs), not only infected host organisms but also a wide array of molecular reagents derived from all life stages of each of the three main human schistosome parasites. As the field of schistosomiasis research rapidly advances, it is likely to become increasingly reliant on omics, transgenics, epigenetics, and microbiome-related research approaches. The SRC has and will continue to monitor and contribute to advances in the field in order to support these research efforts with an expanding array of molecular reagents. In addition to providing investigators with source materials, the SRC has expanded its educational mission by offering a molecular techniques training course and has recently organized an international schistosomiasis-focused meeting. This review provides an overview of the materials and services that are available at the SRC for schistosomiasis researchers, with a focus on updates that have occurred since the original overview in 2008.

Highlights

  • Schistosomes are parasitic trematodes that cause significant liver, intestinal, and pelvic organ disease in millions of people living in tropical regions of the world

  • Continued and vigorous research efforts must be directed at this disease, since only a single World Health Organization (WHO)-approved drug is available for treatment

  • The National Institutes of Health (NIH)–National Institute of Allergy and Infectious Diseases (NIAID) Schistosomiasis Resource Center (SRC) at the Biomedical Research Institute provides investigators with the critical raw materials needed to carry out this important research

Read more

Summary

Background

Schistosomes are parasitic trematodes that cause significant liver, intestinal, and pelvic organ disease in millions of people living in tropical regions of the world. In the course of her research, Dr Knight initially provided select molecular reagents for other schistosomiasis investigators upon request using surplus life cycle materials She recognized that the need existed for a centralized source of well-characterized molecular reagents (of known concentration, purity, restriction enzyme patterns, etc.) and that this would be a logical extension of BRI’s existing life cycle production work. Financial support of the SRC is provided by the “Maintenance, Development and Production of Schistosomiasis Parasites, Reagents and Assays” contract administered by the Parasitology and International Programs Branch (PIPB) of the Division of Microbiology and Infectious Diseases of NIAID (Fig 1) This award supports both the life cycle and molecular work of the SRC

Available Schistosomiasis Research Materials
How to Apply for Materials
Complementary Resources
Education and Outreach
The Symposium for International Research and Innovations in Schistosomiasis
Key Learning Points
Top Five Papers in the Field
Supporting Information

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.